Myers Scott Dunseth 4

What Happened
Myers Scott Dunseth, a director of Dynavax Technologies Corp. (DVAX), disposed of a total of 170,379 shares on February 10, 2026 in connection with Sanofi’s acquisition of Dynavax. Per the merger terms, all common stock was tendered for the $15.50 per-share cash offer, and outstanding RSUs and stock options were cancelled/converted into cash. The gross proceeds from the common-stock portion equal roughly $2.64 million (170,379 × $15.50); option cash-outs depend on each option’s exercise price.

Key Details

• Transaction date: February 10, 2026 (Effective Time of the merger)
• Price: $15.50 per share (the Offer Price paid by purchaser, Sanofi)
• Shares/amounts disposed (sum): 170,379 shares (composed of direct common shares and derivative-related cancellations)
• Footnotes: Transactions occurred under the Agreement and Plan of Merger with Sanofi; RSUs were cancelled and converted to cash; outstanding options were accelerated to vest and converted to cash equal to (shares subject × (Offer Price − exercise price))
• Shares owned after transaction: The filing reports that all common stock held by the reporting person was tendered at the Effective Time; RSUs and options were cancelled/converted per merger terms
• Timeliness: Reported as part of the merger closing (no late-filing flag indicated)

Context
These dispositions are change-of-control cash-outs tied to the Sanofi tender offer and merger—not open-market sales. In M&A scenarios, insiders commonly tender shares and receive merger consideration; option-related amounts reflect cash settlements rather than exercise-and-hold or open-market sales. Such filings document the deal payout and don’t, by themselves, indicate the insider’s market view.